Brief: Lantheus Presents Results From The Primary Analysis Of Phase 3 Pivotal Splash Trial

Lantheus Holdings

15/09/2024 13:54

Sept 15 (Reuters) - Lantheus Holdings Inc  LNTH.O :
    * LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF
PHASE 3
PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER DURING ESMO CONGRESS 2024
    * LANTHEUS HOLDINGS - STUDY MET ITS PRIMARY ENDPOINT
    * LANTHEUS HOLDINGS INC - OVERALL RESPONSE RATE WAS 38.1%
VERSUS.
12.0% FOR ARPI SWITCH ARM
    * LANTHEUS HOLDINGS INC - OVERALL SURVIVAL DATA CONTINUE TO
MATURE

Source text for Eikon:  ID:nGNX3ZqRJf 
Further company coverage:  LNTH.O 

 ((Reuters.Briefs@thomsonreuters.com;))